COVID-19-THE PATIENT HAS TO WITHDRAW FROM THE STUDY DUE TO DISCONTINUE IMP TREATMENT
SUBJECTS WITHDREW FROM THE STUDY DUE TO A RANDOM ERROR.
THE PATIENT UNABLE TO CONTROL ALCOHOL CONSUMPTION AND LIVER FUNCTION DAMAGE AND MULTIPLE LIVER NODULES OF UNKNOWN NATURE AND POOR BLOOD SUGAR CONTROL AND DIABETIC NEPHROPATHY WAS AGGRAVATED
BECAUSE OF THE PATIENT FREQUENT HYPOGLYCEMIA,AND THE PATIENT PERMANENTLY DISCONTINUED AND SUBJECT USE ORIGINAL TREATMENT PLAN
PATIENT HOPE CAN RANDOMIZE INTO IGLARLIXI GROUP AND NOT EXPOSE HER OPINION TO INSULIN GLARGINE BEFORE. DURING THE V2, THE PATIENT RANDOMIZE INTO ANOTHER GROUP. SO PATIENT WITHDRAW FROM THE STUDY.
THE PATIENT COMPLAINED THAT IT WAS INCONVENIENT TO VISIT THE HOSPITAL AND ASKED TO WITHDRAW FROM THE STUDY
PATIENT MEETS EXCLUSION CRITERIA E16: HEPATITIS C ANTIBODY POSITIVE
THE PATIENT'S BLOOD GLUCOSE CONTROL IS NOT GOOD,WITHDRAW FROM THE STUDY
EARLY WITHDRAWAL FROM TREATMENT,BECAUSE OF THE POOR EFFICACY OF THE SUBJECTS
THE SUBJECT WISH TO BE ASSIGNED IN XXX TREATMENT GROUP, ACTUALLY NOT, SUBJECT FELT THE BLOOD GLUCOSE WAS NOT CONTROLLED VERY WELL AFTER TREATED DECIDED TO WITHDRAW.
DURING A TELEPHONE INTERVIEW ON DECEMBER 11,2019, SUBJECTS REQUESTED INFORMED CONSENT TO BE WITHDRAWN AND WITHDRAWN FROM THE TRIAL.SUBJECT WILL REFUSE TO VISIT THE CENTER ON DECEMBER 23,2019 AND WILL
SUBJECT VOLUNTARILY REQUESTS TO WITHDRAW FROM THE STUDY

COVID-19-RUN OUT OF IP.THE PATIENT HAS TO WITHDRAW FROM THE STUDY DUE TO DISCONTINUE IMP TREATMENT.
PATIENT HOPE CAN RANDOMIZE INTO XX GROUP AND NOT EXPOSE HER OPINION TO NIMP BEFORE. DURING THE V2, THE PATIENT RANDOMIZE INTO ANOTHER GROUP. SO PATIENT WITHDRAW FROM THE STUDY.
SUBJECT IS DUE TO WORK CHANGE, SUBJECT COULD NOT KEEP A FREQUENT VISIT PER PROTOCOL REQUIREMENT.
PATIENTS WITH POSITIVE V1 HEPATITIS C MET THE EXCLUSION CRITERIA, BUT WERE RANDOMIZED